Not all possible interactions are listed here. Clinical trials have not revealed any evidence of the potential for abuse, tolerance, or physical dependence; however, systematic studies in humans designed to evaluate these effects have not been performed.In a dose escalation study in patients on chronic levodopa therapy treated with 10 mg of Rasagiline tablets there were three reports of cardiovascular side effects (including hypertension and postural hypotension) which resolved following treatment discontinuation.Rasagiline tablets contain Rasagiline (as the mesylate), a propargylamine-based d rug indicated for the treatment of idiopathic Parkinson’s disease. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.Major Potential Hazard, Moderate plausibility. Each Rasagiline tablet for oral administration contains Rasagiline mesylate equivalent to 0.5 mg or 1 mg of Rasagiline (equivalent to 0.78 mg or 1.56 mg of Rasagiline mesylate).Each Rasagiline tablet also contains the following inactive ingredients: mannitol, corn starch, isopropyl alcohol, Rasagiline tablets are a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease.

Casodex is thought to prevent the growth of prostate cancer by blocking the effects of androgens on the cancer cells. Monoamine oxidase is an enzyme that breaks down serotonin, norepinephrine, Azilect inhibits MAO-B, but it is not clear if Azilect also inhibits MAO-A. Common side effects of Casodex include hot flashes, facial flushing, infections, water retention, anemia, diarrhea, constipation, overall pain, and pain in the back, hips, and stomach. Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of Rasagiline tablets 0.5 mg once daily Rasagiline plasma concentration may increase in patients with hepatic impairment. Common side effects of Azilect include flu like symptoms, headache, nausea, joint pain, upset stomach, depression, falls, constipation, dizziness on standing, dry mouth, rash, hallucinations, vomiting, and difficulty moving. Tell your Azilect's exact mechanism of action is not known; however, by inhibiting MAO-B Serious side effects of Azilect include hypertensive crisis if foods high in tyramine are consumed while taking Azilect.Severe hypertensive reactions have occurred when such drugs were combined with other MAO inhibitors.The following adverse reactions are described in more detail in the product labeling:In Study 1, approximately 5% of the 149 patients treated with Azilect discontinued treatment due to adverse reactions compared to 2% of the 151 patients who received placebo.There were no significant differences in the safety profile based on age or gender.Azilect was studied as an adjunct therapy without levodopa (Study 2), or as an adjunct therapy to levodopa, with some patients also taking dopamine agonists, COMT inhibitors, anticholinergics, or Azilect (rasagiline) is a monoamine oxidase inhibitor (MAOI) used to treat Parkinson's disease. The symptoms? Rasagiline mean steady-state half life is 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.The effectiveness of Rasagiline tablets for the treatment of Parkinson’s disease was established in four 18-to 26-week, randomized, placebo-controlled trials, as initial monotherapy or adjunct therapy.Study 1 was a double-blind, randomized, fixed-dose parallel group, 26-week study in early Parkinson’s disease patients not receiving any concomitant dopaminergic therapy at the start of the study. Increased dopamine levels alleviate the symptoms of Parkinson's disease. Take the...Parkinson's disease is a slowly progressive neurological disease characterized by a fixed inexpressive face, a tremor at rest, slowing of voluntary movements, a gait with short accelerating steps, peculiar posture and muscle weakness, caused by degeneration of an area of the brain called the basal ganglia, and by low production of the neurotransmitter dopamine.